253 related articles for article (PubMed ID: 28545714)
41. Sirtuin 1 inhibition delays cyst formation in autosomal-dominant polycystic kidney disease.
Zhou X; Fan LX; Sweeney WE; Denu JM; Avner ED; Li X
J Clin Invest; 2013 Jul; 123(7):3084-98. PubMed ID: 23778143
[TBL] [Abstract][Full Text] [Related]
42. p21 is decreased in polycystic kidney disease and leads to increased epithelial cell cycle progression: roscovitine augments p21 levels.
Park JY; Schutzer WE; Lindsley JN; Bagby SP; Oyama TT; Anderson S; Weiss RH
BMC Nephrol; 2007 Aug; 8():12. PubMed ID: 17714589
[TBL] [Abstract][Full Text] [Related]
43. Progressive renal distortion by multiple cysts in transgenic mice expressing artificial microRNAs against Pkd1.
Wang E; Hsieh-Li HM; Chiou YY; Chien YL; Ho HH; Chin HJ; Wang CK; Liang SC; Jiang ST
J Pathol; 2010 Nov; 222(3):238-48. PubMed ID: 20814903
[TBL] [Abstract][Full Text] [Related]
44. Steviol retards renal cyst growth through reduction of CFTR expression and inhibition of epithelial cell proliferation in a mouse model of polycystic kidney disease.
Yuajit C; Muanprasat C; Gallagher AR; Fedeles SV; Kittayaruksakul S; Homvisasevongsa S; Somlo S; Chatsudthipong V
Biochem Pharmacol; 2014 Apr; 88(3):412-21. PubMed ID: 24518257
[TBL] [Abstract][Full Text] [Related]
45. Selective targeting of NAMPT by KPT-9274 in acute myeloid leukemia.
Mitchell SR; Larkin K; Grieselhuber NR; Lai TH; Cannon M; Orwick S; Sharma P; Asemelash Y; Zhang P; Goettl VM; Beaver L; Mims A; Puduvalli VK; Blachly JS; Lehman A; Harrington B; Henderson S; Breitbach JT; Williams KE; Dong S; Baloglu E; Senapedis W; Kirschner K; Sampath D; Lapalombella R; Byrd JC
Blood Adv; 2019 Feb; 3(3):242-255. PubMed ID: 30692102
[TBL] [Abstract][Full Text] [Related]
46. Quercetin inhibits renal cyst growth in vitro and via parenteral injection in a polycystic kidney disease mouse model.
Zhu Y; Teng T; Wang H; Guo H; Du L; Yang B; Yin X; Sun Y
Food Funct; 2018 Jan; 9(1):389-396. PubMed ID: 29215110
[TBL] [Abstract][Full Text] [Related]
47. c-Myc is a regulator of the PKD1 gene and PC1-induced pathogenesis.
Parrot C; Kurbegovic A; Yao G; Couillard M; Côté O; Trudel M
Hum Mol Genet; 2019 Mar; 28(5):751-763. PubMed ID: 30388220
[TBL] [Abstract][Full Text] [Related]
48. Integrin-Linked Kinase Signaling Promotes Cyst Growth and Fibrosis in Polycystic Kidney Disease.
Raman A; Reif GA; Dai Y; Khanna A; Li X; Astleford L; Parnell SC; Calvet JP; Wallace DP
J Am Soc Nephrol; 2017 Sep; 28(9):2708-2719. PubMed ID: 28522687
[TBL] [Abstract][Full Text] [Related]
49. Arginine reprogramming in ADPKD results in arginine-dependent cystogenesis.
Trott JF; Hwang VJ; Ishimaru T; Chmiel KJ; Zhou JX; Shim K; Stewart BJ; Mahjoub MR; Jen KY; Barupal DK; Li X; Weiss RH
Am J Physiol Renal Physiol; 2018 Dec; 315(6):F1855-F1868. PubMed ID: 30280600
[TBL] [Abstract][Full Text] [Related]
50. Polycystin-1 regulates ARHGAP35-dependent centrosomal RhoA activation and ROCK signaling.
Streets AJ; Prosseda PP; Ong AC
JCI Insight; 2020 Aug; 5(16):. PubMed ID: 32663194
[TBL] [Abstract][Full Text] [Related]
51. Parallel microarray profiling identifies ErbB4 as a determinant of cyst growth in ADPKD and a prognostic biomarker for disease progression.
Streets AJ; Magayr TA; Huang L; Vergoz L; Rossetti S; Simms RJ; Harris PC; Peters DJ; Ong AC
Am J Physiol Renal Physiol; 2017 Apr; 312(4):F577-F588. PubMed ID: 28077374
[TBL] [Abstract][Full Text] [Related]
52. Comparison of folate-conjugated rapamycin versus unconjugated rapamycin in an orthologous mouse model of polycystic kidney disease.
Kipp KR; Kruger SL; Schimmel MF; Parker N; Shillingford JM; Leamon CP; Weimbs T
Am J Physiol Renal Physiol; 2018 Aug; 315(2):F395-F405. PubMed ID: 29717938
[TBL] [Abstract][Full Text] [Related]
53. Rosiglitazone inhibits insulin-like growth factor‑1-induced polycystic kidney disease cell growth and p70S6 kinase activation.
Liu C; Zhang Y; Yuan L; Fu L; Mei C
Mol Med Rep; 2013 Sep; 8(3):861-4. PubMed ID: 23864113
[TBL] [Abstract][Full Text] [Related]
54. Polycystic kidney disease: pathogenesis and potential therapies.
Takiar V; Caplan MJ
Biochim Biophys Acta; 2011 Oct; 1812(10):1337-43. PubMed ID: 21146605
[TBL] [Abstract][Full Text] [Related]
55. The consequences of increased 4E-BP1 in polycystic kidney disease.
Holditch SJ; Brown CN; Atwood DJ; Pokhrel D; Brown SE; Lombardi AM; Nguyen KN; Hill RC; Lanaspa M; Hopp K; Weiser-Evans MCM; Edelstein CL
Hum Mol Genet; 2019 Dec; 28(24):4132-4147. PubMed ID: 31646342
[TBL] [Abstract][Full Text] [Related]
56. Acute kidney injury induces hallmarks of polycystic kidney disease.
Kurbegovic A; Trudel M
Am J Physiol Renal Physiol; 2016 Oct; 311(4):F740-F751. PubMed ID: 27488998
[TBL] [Abstract][Full Text] [Related]
57. Ganoderma triterpenes retard renal cyst development by downregulating Ras/MAPK signaling and promoting cell differentiation.
Su L; Liu L; Jia Y; Lei L; Liu J; Zhu S; Zhou H; Chen R; Lu HAJ; Yang B
Kidney Int; 2017 Dec; 92(6):1404-1418. PubMed ID: 28709639
[TBL] [Abstract][Full Text] [Related]
58. Salsalate, but not metformin or canagliflozin, slows kidney cyst growth in an adult-onset mouse model of polycystic kidney disease.
Leonhard WN; Song X; Kanhai AA; Iliuta IA; Bozovic A; Steinberg GR; Peters DJM; Pei Y
EBioMedicine; 2019 Sep; 47():436-445. PubMed ID: 31473186
[TBL] [Abstract][Full Text] [Related]
59. Pioglitazone improves the phenotype and molecular defects of a targeted Pkd1 mutant.
Muto S; Aiba A; Saito Y; Nakao K; Nakamura K; Tomita K; Kitamura T; Kurabayashi M; Nagai R; Higashihara E; Harris PC; Katsuki M; Horie S
Hum Mol Genet; 2002 Jul; 11(15):1731-42. PubMed ID: 12095915
[TBL] [Abstract][Full Text] [Related]
60. DH9, a novel PPARγ agonist suppresses the proliferation of ADPKD epithelial cells: An association with an inhibition of β-catenin signaling.
Liu M; Fu L; Liu C; Xiong X; Gao X; Xiao M; Cai H; Hu H; Wang X; Mei C
Invest New Drugs; 2010 Dec; 28(6):783-90. PubMed ID: 19756375
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
